Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.50 |
| ▸ | RAB9A | P51151 | 10/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163872 | 0.89 | EPHX1 (0.51) | EPHX1RAB9AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL162878 | 0.85 | EPHX1 (0.49) | EPHX1RAB9AEPHX2SMN1; SMN2DGAT1 | |
| SCHEMBL163195 | 0.82 | EPHX1 (0.51) | EPHX1RAB9AEPHX2SMN1; SMN2DGAT1 | |
| SCHEMBL163566 | 0.81 | EPHX2 (0.49) | EPHX1RAB9AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL15022218 | 0.81 | EPHX1 (0.44) | EPHX1RAB9AEPHX2SMN1; SMN2DGAT1 | |
| SCHEMBL158865 | 0.79 | EPHX2 (0.51) | EPHX1RAB9AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL15022046 | 0.78 | EPHX1 (0.46) | EPHX1RAB9AEPHX2SMN1; SMN2NPC1 | |
| SCHEMBL161526 | 0.77 | DGAT1 (0.60) | EPHX1RAB9AEPHX2SMN1; SMN2DGAT1 | |
| SCHEMBL163121 | 0.76 | DGAT1 (0.59) | RAB9AEPHX2SMN1; SMN2DGAT1NPC1 | |
| SCHEMBL163790 | 0.74 | DGAT1 (0.60) | RAB9AEPHX2SMN1; SMN2DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | EPHX1 786/4885RAB9A 1781/4885EPHX2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.